Richtlijn Sikkelcelziekte
Auteur: Bart Biemond
U wordt hiervoor verwezen naar de landelijke richtlijn uit okober 2017
Inhoud van de richtlijn
- Samenstelling werkgroep ..............................................................................................................................2
- Belangenconflict: ......................................................................................................................................3
- Inleiding .................................................................................................................................................... 4
- Monitoren orgaanschade ...........................................................................................................................5
- Acute vaso-occlusieve crise ......................................................................................................................8
- Anticonceptie ............................................................................................................................................ 10
- Bloedtransfusie ..........................................................................................................................................12
- Hemolytische transfusiereactie ..................................................................................................................16
- Hydroxycarbamide .....................................................................................................................................18
- Peri-operatieve zorg ...................................................................................................................................21
- Infectieprofylaxe..........................................................................................................................................24
- Acute chest syndrome ................................................................................................................................27
- Priapisme ....................................................................................................................................................29
- Retinopathie ................................................................................................................................................30
- Pulmonale hypertensie ................................................................................................................................32
- Avasculaire botnecrose ...............................................................................................................................34
- Galsteenlijden ............................................................................................................................................. 36
- Levercrise.....................................................................................................................................................38
- Nefropathie ..................................................................................................................................................40
- Cardiomyopathie ..........................................................................................................................................42
- Miltsequestratie ............................................................................................................................................ 43
- Ischemisch CVA.............................................................................................................................................45
- Ulcus cruris ....................................................................................................................................................48
- IJzerstapeling en chelatietherapie ................................................................................................................. 50
- Appendix A – SORT Grading .........................................................................................................................52
- Appendix B - Verantwoording ....................................................................................................................... 54
Onderzoek
Klik hier om door te gaan naar de studies die geopend zijn in het AMC bij een sikkelcelcrise
Documenten
Links/literatuur
JHM-SCC-107 versie 3
Geldig 24 november 2018
Onder beheer van afdeling:
Hematologen